The effect of tocilizumab on preventing relapses in adult-onset still's disease: A retrospective, single-center study

Modern Rheumatology

Volumn 25, Issue 3, 2015, Pages 401-404

  Nishina, Naoshi ^a   Kaneko, Yuko ^a   Kameda, Hideto ^a,b   Takeuchi, Tsutomu ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOHO UNIVERSITY OHASHI MEDICAL CENTER   (Japan)

Author keywords

Adult onset Still's disease; Glucocorticoids; Relapse; Tocilizumab

Indexed keywords

C REACTIVE PROTEIN; TOCILIZUMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; ADULT ONSET STILL DISEASE; ARTICLE; CLINICAL ASSESSMENT; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; TREATMENT RESPONSE; MIDDLE AGED; SECONDARY PREVENTION; STILL'S DISEASE, ADULT-ONSET; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SECONDARY PREVENTION; STILL'S DISEASE, ADULT-ONSET; TREATMENT OUTCOME;

EID: 84929459963     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2014.973659     Document Type: Article

References (12)

1. Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371(9617): 998-1006.
2. De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al.; PRINTO; PRCSG. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012; 367(25):2385-95.
3. Suematsu R, Ohta A, Matsuura E, Takahashi H, Fujii T, Horiuchi T, et al. Therapeutic response of patients with adult Still's disease to biologic agents: multicenter results in Japan. Mod Rheumatol. 2012;22(5):712-9.
4. Puechal X, DeBandt M, Berthelot JM, Breban M, Dubost JJ, Fain O, et al.; Club Rhumatismes Et Inflammation. Tocilizumab in refractory adult Still's disease. Arthritis Care Res (Hoboken). 2011;63(1): 155-9.
5. Elkayam O, Jiries N, Dranitzki Z, Kivity S, Lidar M, Levy O, et al. Tocilizumab in adult-onset Still's disease: the Israeli experience. J Rheumatol. 2014;41(2):244-7.
6. Bannai E, Yamashita H, Kaneko S, Ueda Y, Ozaki T, Tsuchiya H, et al. Successful tocilizumab therapy in seven patients with refractory adult-onset Still's disease. Mod Rheumatol. 2014 Apr 3 (E-pub ahead of print).
7. Ortiz-Sanjuan F, Blanco R, Calvo-Rio V, Narvaez J, Rubio Romero E, Olive A, et al. Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still's disease: multicenter retrospective open-label study of thirty-four patients. Arthritis Rheumatol. 2014; 66(6):1659-65.
8. Cipriani P, Ruscitti P, Carubbi F, Pantano I, Liakouli V, Berardicurti O, Giacomelli R. Tocilizumab for the treatment of adult-onset Still. s disease: results from a case series. Clin Rheumatol. 2014;33(1): 49-55.
9. Pouchot J, Sampalis JS, Beaudet F, Carette S, Decary F, Salusinsky-Sternbach M, et al. Adult Still 's disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore). 1991;70(2): 118-36.
10. Fautrel B. Adult-onset Still disease. Best Pract Res Clin Rheumatol. 2008;22(5):773-92.
11. Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol. 1992;19(3):424-30.
12. Wakai K, Ohta A, Tamakoshi A, Ohno Y, Kawamura T, Aoki R, et al. Estimated prevalence and incidence of adult Still's disease: findings by a nationwide epidemiological survey in Japan. J Epidemiol. 1997; 7(4):221-5.